Menu

hyperCORE International's COVID- 19 Capabilities

Experience and Quality
Streamlined

  • Seroprevalence occur rence up to 10% in hyperCORE communities
  • Capacity to randomize up to 5,000 COVID-19 vaccine patients and 100 treatment/prevention patients per week
  • Access within our communities to 10,000+ COVID-19 tests administered per day, 5,000+ COVID-19 patients per month, and more than 1M patients in our databases for prevention trials
  • 100,000+ Patients Enrolled in Vaccine Trials
  • Experience in 40+ Infectious Disease Indications
  • 1,100+ Respiratory Trials Completed ( Including Severe Pneumonia)

Partner Highlights

AGA Clinical Trials is a top enroller in COVID-19 treatment trials.

Benchmark Research has enrolled over 3,000 patients in COVID-19 trials.

FOMAT Medical Research is a top enroller in COVID-19 vaccine and treatment trials and won Oxnard Innovation Award for work on COVID- 19.

IACT Health has enrolled over 1,500 + patients in COVID-19 trials, 47% minorities, and achieved 161% contracted targets.

QCR Clinical Research successfully initiated an outreach initiative with the Omaha Native America Tribe for participation in COVID-19 vaccine trials.

One Network for One Solution

  • Single Contract and Centralized Budget
  • Central IRBs
  • All Sites Virtual Trial Certified
  • Virtual/Tele/Electronic Visit Capable
  • Remote and Mobile Units Available
  • Multiple Hospital Affiliations
  • Locations Across North and South America